SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) — Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that Histogen’s financial results for the third quarter will be released after the close of market on Wednesday, November 10, 2021.
About Histogen Inc.
Histogen Inc. is a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. Histogen’s innovative technology platform utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells. Histogen’s proprietary, reproducible manufacturing process provides targeted solutions across a broad range of therapeutic indications, including joint cartilage regeneration, spinal disk repair, tendon, ligament and other soft tissue repair. For more information, please visit www.histogen.com.
CONTACT:
Susan A. Knudson
Executive Vice President & CFO
Histogen Inc.
ir@histogen.com
Brings 25 Years of Healthcare Technology Leadership to CompanyMOBILE, Ala.--(BUSINESS WIRE)--TruBridge, Inc. (NASDAQ: TBRG), a…
MIAMI, Jan. 2, 2025 /PRNewswire/ -- Motion game consoles, now relics of the past, once…
SANTA CLARA, Calif., Jan. 2, 2025 /PRNewswire/ -- Osteoid Inc. announces that Invivo and TX Studio…
NEW YORK, Jan. 2, 2025 /PRNewswire/ -- QALO, the pioneer of silicone rings designed for…
Providing Peace of Mind for Caregivers and Safety for Loved Ones LAS VEGAS, Jan. 2,…
SAN FRANCISCO, Jan. 2, 2025 /PRNewswire/ -- Relax VR, a leader in multisensory virtual reality…